A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax (R))

Grants

Funding Acknowledgements

SJ Harrison and HM Prince have received grant funding and honoraria from Celgene. SE Bates recieves funding via Cooperative Research and Development Agreement between NCI and Celgene. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.